High-risk human papillomavirus testing as a primary screening for cervical cancer: position statement by the Korean Society of Obstetrics and Gynecology and the Korean Society of Gynecologic Oncology / 부인종양
Journal of Gynecologic Oncology
;
: 31-2020.
Artículo
en Inglés
| WPRIM
| ID: wpr-782088
ABSTRACT
knowledge regarding high-risk human papillomavirus (hrHPV) testing as a primary screening for cervical cancer, the Korean Society of Obstetrics and Gynecology and the Korean Society of Gynecologic Oncology support the following scientific facts• Compared to cytology, hrHPV screening has higher sensitivity and detects more cases of high-grade cervical intraepithelial neoplasia.• Qualified hrHPV testing can be considered as an alternative primary screening for cervical cancer to the current cytology method.• The starting age of primary hrHPV screening should not be before 25 years because of possible overtreatment in this age, which has a high human papillomavirus (HPV) prevalence but rarely progresses to cancer. The screening interval should be no sooner than every 3 years and no longer than every 5 years.• Before the introduction of hrHPV screening in Korea, research into comparative effectiveness of primary hrHPV screening for cervical cancer should be conducted to determine the appropriate HPV assay, starting age, and screening interval.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Displasia del Cuello del Útero
/
Neoplasias del Cuello Uterino
/
Tamizaje Masivo
/
Prevalencia
/
Detección Precoz del Cáncer
/
Pruebas de ADN del Papillomavirus Humano
/
Uso Excesivo de los Servicios de Salud
/
Ginecología
/
Corea (Geográfico)
/
Métodos
Tipo de estudio:
Estudio diagnóstico
/
Estudio de etiología
/
Estudio de prevalencia
/
Estudio de tamizaje
Límite:
Humanos
País/Región como asunto:
Asia
Idioma:
Inglés
Revista:
Journal of Gynecologic Oncology
Año:
2020
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS